HC Wainwright Issues Pessimistic Estimate for SPRO Earnings

Spero Therapeutics, Inc. (NASDAQ:SPRO) – Investment analysts at HC Wainwright dropped their FY2024 EPS estimates for Spero Therapeutics in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.23) per share for the year, down from their previous estimate of ($0.75). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.84) EPS.

Other equities analysts also recently issued research reports about the stock. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th.

Spero Therapeutics Stock Performance

Shares of SPRO opened at $1.16 on Wednesday. Spero Therapeutics has a 1 year low of $1.01 and a 1 year high of $1.89. The company has a market cap of $63.24 million, a price-to-earnings ratio of 16.57 and a beta of 0.59. The firm has a fifty day moving average of $1.25 and a 200-day moving average of $1.32.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SPRO. Virtu Financial LLC acquired a new stake in Spero Therapeutics in the 1st quarter valued at about $31,000. Renaissance Technologies LLC raised its holdings in Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after buying an additional 121,492 shares during the period. Acadian Asset Management LLC raised its holdings in Spero Therapeutics by 40.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after buying an additional 309,262 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares during the period. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.